Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

• Published in: Blood Vol. 125; no. 6; pp. 901 - 906
• Main Authors: Valent, Peter, Hadzijusufovic, Emir, Schernthaner, Gerit-Holger, Wolf, Dominik, Rea, Delphine, le Coutre, Philipp
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 05.02.2015
• Subjects: Fusion Proteins, bcr-abl - antagonists & inhibitors; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Protein Kinase Inhibitors - adverse effects; Vascular Diseases - chemically induced; Vascular Diseases - complications

Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events, several types of vascular adverse e...